Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Trastuzumab, and Chemotherapy in HER2+ Advanced Colorectal Cancer
NCT05193292Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in colorectal cancer (CRC), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05193292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05193292.